UCB (OTCMKTS:UCBJY) Raised to Moderate Sell at Jefferies Financial Group

UCB (OTCMKTS:UCBJY) was upgraded by equities research analysts at Jefferies Financial Group to a “moderate sell” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities analysts have also issued reports on UCBJY. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research report on Thursday, June 11th. Finally, Wolfe Research upgraded UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, UCB currently has a consensus rating of “Hold”.

UCB Stock Up 1.1%

OTCMKTS UCBJY opened at $143.03 on Monday. The firm’s fifty day moving average price is $144.16 and its 200 day moving average price is $147.52. UCB has a 12 month low of $94.75 and a 12 month high of $168.76. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.